Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

(2018) M. Catherine Pietanza et al.   JOURNAL OF CLINICAL ONCOLOGY

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

(2017) Corinne Faivre-Finn et al.   LANCET ONCOLOGY

Randomized phase 2 study of investigational aurora A kinase (AAK) inhibitor alisertib (MLN8237) + paclitaxel (P) vs placebo + P as second line therapy for small-cell lung cancer (SCLC)

(2016) T.K. Owonikoko et al.   ANNALS OF ONCOLOGY

Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508)

(2016) Chandra P. Belani et al.   CANCER

Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer

(2016) Louise Carter et al.   NATURE MEDICINE

Protocol for the CONVERT trial—Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status

(2016) Corinne Faivre-Finn et al.   BMJ Open

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer

(2014) Cassandra L Hodgkinson et al.   NATURE MEDICINE

Circulating tumor cells as a prognostic factor in patients with small cell lung cancer

(2014) SATOSHI IGAWA et al.   Oncology Letters

Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer

(2012) Jian-Mei Hou et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating tumour cells in non-metastatic breast cancer: a prospective study

(2012) Anthony Lucci et al.   LANCET ONCOLOGY

External quality assurance of circulating tumor cell enumeration using the CellSearch® system: A feasibility study

(2010) Jaco Kraan et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Circulating tumour cells: their utility in cancer management and predicting outcomes

(2010) Matthew G. Krebs et al.   Therapeutic Advances in Medical Oncology

Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy

(2009) Jian-Mei Hou et al.   AMERICAN JOURNAL OF PATHOLOGY

Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer

(2009) S. J. Cohen et al.   ANNALS OF ONCOLOGY

Circulating Tumor Cell as a Diagnostic Marker in Primary Lung Cancer

(2009) F. Tanaka et al.   CLINICAL CANCER RESEARCH

Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables

(2008) J. Sastre et al.   ANNALS OF ONCOLOGY

Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

(2008) J. S. de Bono et al.   CLINICAL CANCER RESEARCH